https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-26 / J Transl Med 2019 11;17(1):391
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-26 / J Transl Med 2019 11;17(1):3912019-11-26 00:00:002020-08-26 13:58:47A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-25 / J Immunol Res 2019;2019:9631515
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-25 / J Immunol Res 2019;2019:96315152019-11-25 00:00:002019-11-25 00:00:00Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-15 / Hum Vaccin Immunother 2020 04;16(4):742-755
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-15 / Hum Vaccin Immunother 2020 04;16(4):742-7552019-11-15 00:00:002019-11-15 00:00:00Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-14 / J Immunother Cancer 2019 Nov;7(1):302
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-14 / J Immunother Cancer 2019 Nov;7(1):3022019-11-14 00:00:002019-11-14 00:00:00Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-14 / Front Oncol 2019;9:1169
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-14 / Front Oncol 2019;9:11692019-11-14 00:00:002019-11-14 00:00:00Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-01 / Am J Cancer Res 2019;9(11):2456-2468
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-01 / Am J Cancer Res 2019;9(11):2456-24682019-11-01 00:00:002019-11-01 00:00:00Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-01 / Int J Cancer 2020 01;146(2):531-541
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-01 / Int J Cancer 2020 01;146(2):531-5412019-11-01 00:00:002020-12-14 17:16:09Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-10-29 / Future Sci OA 2019 Oct;5(10):FSO435
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-10-29 / Future Sci OA 2019 Oct;5(10):FSO4352019-10-29 00:00:002019-10-29 00:00:00Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN in combination with chemotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-10-24 / Immunology 2020 01;159(1):75-87
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-10-24 / Immunology 2020 01;159(1):75-872019-10-24 00:00:002019-10-24 00:00:00Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-10-17 / Pathol. Res. Pract. 2019 Dec;215(12):152691
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-10-17 / Pathol. Res. Pract. 2019 Dec;215(12):1526912019-10-17 00:00:002019-10-17 00:00:00Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies
